Alpha Compute Corp · NASDAQ:ALP
Alpha Compute — Portage Biotech — Merger or Acquisition (July 2022)
12 slides from Alpha Compute's merger presentation, Jul 7, 2022
Slide 1: Tarus Acquisition Announcement
Tarus Acquisition Announcement 1 Nasdaq: PRTG July 2022
Slide 2: Legal Disclaimer
Legal Disclaimer 2 This presentation is for information purposes only. This presentation does not constitute a general advertisement or general solicitation or an offer to sell or a solicitation to buy any securities in any jurisdiction. Such an offer can only be made by prospectus or other authoriz
Slide 3: Overview of Transaction
Overview of Transaction • Portage pays 2,425,999 shares plus assumption of $3M in liabilities • Up to $32M in additional stock or cash payments depending on development and commercial milestones • Entered into a committed share purchase agreement for up to $30 million • 36 - month term, price is bas
Slide 4: iNKT Agonist and Adenosine Inhibitor Platforms Pipeline
iNKT Agonist Platform ASSET TECHNOLOGY ASSET INDICATION STAGE Adenosine Inhibitor Platform ASSET TECHNOLOGY ASSET INDICATION STAGE Novel Pipeline with numerous small molecule broad immune engagers PORT - 6 A2AR Inhibitor TT - 10 A2A exp Solid Tumors Phase 1a/1b PORT - 7 A2BR Inhibitor TT - 4 A2B exp
Slide 5: Adenosine Portfolio
Adenosine Portfolio PORT - 6, PORT - 7, PORT - 8, PORT - 9 A2AR Inhibitor A2BR Inhibitor A2AR/A2BR Dual Inhibitor Gut - restricted A2BR Inhibitor
Slide 6: Adenosine Pathway - High Priority Target for Immunotherapeutic Intervention
6 Targeting Adenosine in Cancer Immunotherapy to Enhance T - Cell Function; Virgano, et a l; Frontiers in Immunology 2019 used under CC BY 4.0 Adenosine Pathway - High Priority Target for Immunotherapeutic Intervention T cell ↓ Th1/Th2 - signature cytokines (A2AR, A2BR) ↓ proliferation (A2AR, A2BR)
Slide 7: Clinical Evidence from Other Adenosine Agents
7 Clinical Evidence from Other Adenosine agents • CD73: ESMO 2021 AZ presents COAST Phase II Trial results for Oleclumab (anti CD73) + Durvalumab (anti PD - L - 1) Combination in Patients with Unresectable Stage III Non - Small - Cell Lung Cancer has PFS benefit • A2A: less mature, lessons from iTeo
Slide 8: A2A: More Selective, More Potent, More Durable
8 1 AACR 2019 2 Cancer Immunology Research 2018, 3 ASCO GU 2020, SITC 2018. BEST IN CLASS A2A: More Selective, More Potent, More Durable Key Parameters PORT - 6 Portage EOS - 850 iTeos 1 CPI - 444 Corvus 2 AB928 Arcus 3 Significance Potency (cAMP functional inhibition of A2AR) IC50 0.40nM 2.24nM 17.
Slide 9: PORT-7: Highly Selective and Potent A2B Adenosine Receptor Antagonist
9 PORT - 7: Highly Selective and Potent A2B Adenosine Receptor Antagonist High potency and selectivity may provide important safety and efficacy advantages • Activity in 4T1, CT26, and other disease models (Asthma, fibrosis, sickle cell) • IND approved for pro - drug Binding affinity Functional anta
Slide 10: PORT-8: Dual A2A/A2B Improved Profile vs. Arcus Dual Inhibitor AB928
(1) Competitive inhibition of receptor signaling 10 (2) Arcus presentation 13X More potent for A2BR inhibition 3X More potent for A2AR 4X Higher selectivity against A1R PORT - 8: Dual A2A/A2B Improved Profile vs. Arcus Dual Inhibitor AB928 • Highly potent dual A2AR / A2BR antagonists with low nanomo
Slide 11: Trial of Adenosine A2A and A2B in Solid Tumors (TOAST-1 study)
T rial O f A denosine a2a and a2b in S olid T umors ( TOAST - 1 study) A2BR indications: Colorectal Cancer, Non - small Cell Lung Cancer, Endometrial Cancer, Ovarian Cancer with high A2B expression A2AR indications: Prostate Cancer, Non - small Cell Lung Cancer, Head & Neck Cancer, Renal Cell Cancer
Slide 12: Accelerating Development in Untapped Growth Areas of I/O
Accelerating Development in Untapped Growth Areas of I/O Capital Efficient Portfolio Expansion into Adenosine Pathway • Doubled clinical candidates via modest initial capital outlay • Differentiated I/O portfolio with multiple clinical data reads over the next 2 years De - risked Research & Developm